Tazeen Ahmad
Stock Analyst at B of A Securities
(2.37)
# 2,471
Out of 4,734 analysts
189
Total ratings
41.84%
Success rate
-0.53%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $14.11 | +55.92% | 5 | Dec 19, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $79 → $46 | $4.67 | +885.01% | 3 | Dec 18, 2024 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $22 | $8.75 | +151.43% | 1 | Dec 18, 2024 | |
| PEPG PepGen | Maintains: Neutral | $10 → $6 | $2.08 | +189.16% | 2 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $61 → $47 | $30.13 | +55.99% | 6 | Nov 6, 2024 | |
| INCY Incyte | Upgrades: Buy | $68 → $90 | $73.47 | +22.50% | 5 | Oct 30, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.51 | +57.73% | 5 | Oct 17, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $307 → $314 | $264.99 | +18.50% | 2 | Oct 14, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Neutral | $48 → $52 | $57.52 | -9.60% | 7 | Oct 14, 2024 | |
| SAGE Sage Therapeutics | Maintains: Underperform | $11 → $6 | $6.94 | -13.54% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $131.06 | +45.73% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $117.25 | +27.93% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $4.00 | -50.00% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $29 | $23.04 | +25.87% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 | $39.74 | +91.24% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $647.39 | -6.24% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $25 → $32 | $45.25 | -29.28% | 15 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $116.79 | +82.38% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $41.28 | +84.11% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $17.89 | +22.97% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.99 | +503.02% | 1 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $1.35 | +937.04% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.17 | +139.81% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.32 | +354.55% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.09 | +85.41% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $0.5 | $1.15 | -56.52% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $19.12 | -42.47% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $7.61 | +31.41% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.76 | +13.64% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.22 | +391.80% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $12.77 | +17.46% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $78.26 | -23.33% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.53 | +945.75% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $18.57 | +492.35% | 1 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $6.58 | +553.50% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $187.90 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $4.52 | +6,537.17% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.90 | +904.91% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $22.84 | +110.16% | 6 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $102 | $145.88 | -30.08% | 2 | May 1, 2018 |
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $14.11
Upside: +55.92%
4D Molecular Therapeutics
Dec 18, 2024
Maintains: Buy
Price Target: $79 → $46
Current: $4.67
Upside: +885.01%
KalVista Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $8.75
Upside: +151.43%
PepGen
Nov 18, 2024
Maintains: Neutral
Price Target: $10 → $6
Current: $2.08
Upside: +189.16%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $30.13
Upside: +55.99%
Incyte
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $73.47
Upside: +22.50%
Amicus Therapeutics
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.51
Upside: +57.73%
Alnylam Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $307 → $314
Current: $264.99
Upside: +18.50%
Rhythm Pharmaceuticals
Oct 14, 2024
Maintains: Neutral
Price Target: $48 → $52
Current: $57.52
Upside: -9.60%
Sage Therapeutics
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $6.94
Upside: -13.54%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $131.06
Upside: +45.73%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $117.25
Upside: +27.93%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $4.00
Upside: -50.00%
Sep 4, 2024
Maintains: Buy
Price Target: $25 → $29
Current: $23.04
Upside: +25.87%
Jun 25, 2024
Maintains: Buy
Price Target: $76
Current: $39.74
Upside: +91.24%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $647.39
Upside: -6.24%
Jun 21, 2024
Maintains: Underperform
Price Target: $25 → $32
Current: $45.25
Upside: -29.28%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $116.79
Upside: +82.38%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $41.28
Upside: +84.11%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $17.89
Upside: +22.97%
May 8, 2024
Initiates: Buy
Price Target: $12
Current: $1.99
Upside: +503.02%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $1.35
Upside: +937.04%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.17
Upside: +139.81%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.32
Upside: +354.55%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.09
Upside: +85.41%
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $1.15
Upside: -56.52%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $19.12
Upside: -42.47%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $7.61
Upside: +31.41%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.76
Upside: +13.64%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.22
Upside: +391.80%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $12.77
Upside: +17.46%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $78.26
Upside: -23.33%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.53
Upside: +945.75%
Sep 9, 2021
Initiates: Buy
Price Target: $110
Current: $18.57
Upside: +492.35%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $6.58
Upside: +553.50%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $187.90
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $4.52
Upside: +6,537.17%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.90
Upside: +904.91%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $22.84
Upside: +110.16%
May 1, 2018
Maintains: Buy
Price Target: $101 → $102
Current: $145.88
Upside: -30.08%